Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite

Luteinizing Hormone-Releasing Hormone Agonist Triptorelin and Antagonist Cetrorelix Inhibit EGF-Induced c-fos Expression in Human Gynecological Cancers

By Grundker C.   Volker P.   Schulz K.-D.   Emons G.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 194-202

Elsevier

Access to resources Recommend Favorite

Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II

By Jungwirth A.   Pinski J.   Galvan G.   Halmos G.   Szepeshazi K.   Cai R.Z.   Groot K.   Vadillo-Buenfil M.   Schally A.V.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1141-1148

Elsevier

Access to resources Recommend Favorite

A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma

By Sorensen P.   Hoyer M.   Jakobsen A.   Malmstrom H.   Havsteen H.   Bertelsen K.  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 58-62

Elsevier

Access to resources Recommend Favorite